SCHEMBL5118948

SCHEMBL5118948

CC(C)(C)OC(=O)N1CCC2(CC1)CC(C(=O)Nc1ccc(Cl)cn1)=NO2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.56
NR3C1 P04150 2/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
F13A1 P00488 1/20 0.42
TGM2 P21980 1/20 0.42
TGM1 P22735 1/20 0.42
STS P08842 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
TSHR P16473 3/20 0.41
RAB9A P51151 3/20 0.41
TP53 P04637 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
PTK2 Q05397 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1457290 0.89 GPR119 (0.45) GPR119NR3C1MEN1KMT2ASMN1; SMN2
SCHEMBL5114594 0.83 SMN1; SMN2 (0.57) GPR119MEN1KMT2ASTSSMN1; SMN2
SCHEMBL12825009 0.79 L3MBTL1 (0.46) KMT2ASMN1; SMN2TSHRRAB9ATP53
SCHEMBL5123898 0.78 MEN1 (0.48) GPR119MEN1KMT2ASTSSMN1; SMN2
SCHEMBL3492228 0.78 F13A1 (0.46) NR3C1MEN1KMT2AF13A1TGM2
SCHEMBL1639199 0.77 GPR119 (0.57) GPR119SMN1; SMN2TSHRTP53MAPT
SCHEMBL13811458 0.76 GPR119 (0.57) GPR119SMN1; SMN2TSHRTP53MAPT
SCHEMBL3492486 0.76 TDP1 (0.44) MEN1KMT2AF13A1TGM2TGM1
SCHEMBL2400325 0.75 GPR119 (0.54) GPR119MEN1KMT2ASMN1; SMN2TP53
SCHEMBL12901537 0.75 GPR119 (0.49) GPR119MEN1KMT2ASTSSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292625-A1 Substituted spiro compounds and their use for producing pain-relief medicaments Grünenthal GmbH (DE) 2011-03-09 EP disclosed
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs GRUENENTHAL GMBH (DE) 2008-09-04 US disclosed
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs GRUENENTHAL GMBH (DE) 2008-09-04 US disclosed
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs GRUENENTHAL GMBH (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs REN, PKD1, NR3C2 GPR119 2131/4885NR3C1 564/4885MEN1 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.